Skip to main content
Erschienen in: Journal of Experimental & Clinical Cancer Research 1/2020

Open Access 01.12.2020 | Correction

Correction to: LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway

verfasst von: Deyao Shi, Fashuai Wu, Shidai Mu, Binwu Hu, Binlong Zhong, Feng Gao, Xiangcheng Qing, Jianxiang Liu, Zhicai Zhang, Zengwu Shao

Erschienen in: Journal of Experimental & Clinical Cancer Research | Ausgabe 1/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13046-019-1363-0.
Correction to: J Exp Clin Cancer Res
https://doi.org/10.1186/s13046-019-1363-0
In the original publication of this manuscript [1], Fig. 5a needs to be revised, and adjustments have also been made to the captions for Figs. 2, 4, 5 and S1 to improve clarity for the reader. The revised Fig. 5 and captions for Figs. 2,4 and S1 are shown below:
Fig. 2 Effect of AFAP1-AS1 knockdown on the apoptosis, cell cycle, migration, invasion, actin filament integrity and vasculogenic mimicry formation of OS cells. a and b AFAP1-AS1 knockdown induced apoptosis and resulted in G0/G1 cell cycle arrest. c and d AFAP1-AS1 knockdown inhibited migration and invasion ability of OS cells. e In the AFAP1-AS1 knockdown group, the expression of cleaved Caspase 3, Bax were increased and the expression of Bcl-2, Cyclin D1 and MMP-9 were decreased compared to the scrambled group. f AFAP1-AS1 knockdown inhibited the VM formation ability of OS cells. g AFAP1-AS1 knockdown in OS cells induced loss of actin filament integrity. The integrity and fluorescence intensity of actin filament in osteosarcoma cells were obviously decreased. *P < 0.05, **P < 0.01. In Fig. 2e / Fig. 4a / Fig. 4b / Fig. S1, the same GAPDH images were used to normalize in multiple panels under the same experimental treatments.
Fig. 4 Effect of AFAP1-AS1 knockdown on molecular expression of OS cells and AFAP1-AS1 knockdown-inhibited EMT is mediated via RhoC/ROCK1/p38MAPK/Twsit1 signaling pathway. a AFAP1-AS1 knockdown in OS cells led to significantly decreased expression of mesenchymal markers (Ncadherin and Vimentin) and increased expression of epithelial marker E-cadherin. b In the AFAP1-AS1 knockdown group, the expression of RhoC, ROCK1, p-p38MAPK and Twsit1 was decreased compared to the scrambled group. c RIP assay demonstrated that AFAP1-AS1 interacted with RhoC in OS cells. d, e and f Overexpression of RhoC in AFAP1-AS1 knockdown OS cells could rescue AFAP1-AS1 downregulation-induced inhibition of cell migration, invasion, EMT, and the expression level of ROCK1, phosphorylated p38MAPK and Twist1 were rescued. g and h Both downregulating AFAP1-AS1 and RhoC, the expression of Twist and EMT of OS cells were inhibited further. *P < 0.05, **P < 0.01, ***P < 0.001. In Fig. 2e / Fig. 4a / Fig. 4b/ Fig. S1, Fig. 4f / Fig. 4d and Fig. 4g / Fig. 4h, the same GAPDH images were used to normalize in multiple panels under the same experimental treatments.
Figure S1. Knockdown of AFAP1-AS1 exerted no significant alteration on AFAP1 mRNA and protein expression. In Fig. 2e / Fig. 4a / Fig. 4b / Fig. S1, the same GAPDH images were used to normalize in multiple panels under the same experimental treatments.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Shi, et al. LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway. J Exp Clin Cancer Res. 2019;38:375.CrossRef Shi, et al. LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway. J Exp Clin Cancer Res. 2019;38:375.CrossRef
Metadaten
Titel
Correction to: LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway
verfasst von
Deyao Shi
Fashuai Wu
Shidai Mu
Binwu Hu
Binlong Zhong
Feng Gao
Xiangcheng Qing
Jianxiang Liu
Zhicai Zhang
Zengwu Shao
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Journal of Experimental & Clinical Cancer Research / Ausgabe 1/2020
Elektronische ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-020-01574-2

Weitere Artikel der Ausgabe 1/2020

Journal of Experimental & Clinical Cancer Research 1/2020 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.